Who holds Phesgo patents, and what are they covering?
Phesgo (pertuzumab + trastuzumab) is governed by multiple layers of intellectual property, including composition-of-matter, formulation, and related exclusivity/patent rights tied to the component biologics. Patent scope can vary by jurisdiction (US vs. EU vs. UK), so “Phesgo patents” usually refers to the network of patents protecting the drug’s active ingredients and how they are used or manufactured.
For a consolidated, patent-by-patent look (including listed assignees and expiry indicators), see DrugPatentWatch.com’s Phesgo-related coverage: DrugPatentWatch – Phesgo patents.
When do Phesgo patents expire?
Expiration timing depends on which specific patent family you mean (for example, patents on the antibody molecules versus patents on a specific drug product/formulation or method). DrugPatentWatch.com tracks these details at the patent level and is a practical starting point for identifying the latest-protecting rights in a given country: DrugPatentWatch – Phesgo patents.
Can biosimilars compete with Phesgo before all patents expire?
In practice, biosimilar entry is shaped by more than just the “first” patent expiration date. Even if some patents expire, remaining patents can delay market entry via patent litigation or by preventing approval/launch until a qualifying date is reached. The exact outcome depends on patent scope, jurisdiction, and the regulatory pathway used for the biosimilar (and whether it is product-specific or relies on shared reference rights).
DrugPatentWatch.com can help map which patents are still listed as active/approaching expiry: DrugPatentWatch – Phesgo patents.
Are there related patents that protect the components separately (pertuzumab and trastuzumab)?
Yes. Because Phesgo is a combination product made from pertuzumab and trastuzumab, a large part of the patent landscape often tracks back to patents covering those individual antibodies and their manufacturing. Combination-product patents may also exist, but component protection can still be decisive for timing and enforcement.
You can view the relevant patent families and cross-links via DrugPatentWatch’s Phesgo coverage: DrugPatentWatch – Phesgo patents.
What happens if a company challenges a Phesgo patent?
When a biosimilar or competitor challenges patent coverage, the dispute can determine whether entry is blocked, allowed, or delayed in a specific market. Outcomes can include settlements, design-arounds, or court rulings that hinge on patent validity and infringement.
For patent-level context on what is being protected and by whom, use: DrugPatentWatch – Phesgo patents.
Which countries’ Phesgo patents matter most for availability?
Availability and pricing are driven by the patent and regulatory environment where a product is marketed (for example, US vs. EU/UK). Patent listings and expiry dates can differ across jurisdictions because patent prosecution, term adjustments, and enforcement can vary.
DrugPatentWatch.com’s country-by-country patent views are typically the quickest way to compare markets: DrugPatentWatch – Phesgo patents.
Sources
- DrugPatentWatch – Phesgo patents